Heavy marijuana users show increased serum apolipoprotein C-III levels: Evidence from proteomic analyses

Molecular Psychiatry

Volumn 15, Issue 1, 2010, Pages 101-112

  Jayanthi, S ^a   Buie, S ^a   Moore, S ^b   Herning, R I ^a   Better, W ^a   Wilson, N M ^a   Contoreggi, C ^c   Cadet, J L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Ciphergen Biosystems   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Apolipoproteins; Cannabis; Cerebrovascular and cardiovascular risk factors; Protein profiling

Indexed keywords

APOLIPOPROTEIN C3; APOLIPOPROTEIN C3 ANTIBODY; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; DRONABINOL; PROTEIN ANTIBODY; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANNABIS ADDICTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOPRECIPITATION; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; APOLIPOPROTEIN C-III; BIOLOGICAL MARKERS; FEMALE; HUMANS; LIPIDS; MALE; MARIJUANA ABUSE; MOLECULAR WEIGHT; PROTEIN ARRAY ANALYSIS; PROTEINS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUBCELLULAR FRACTIONS; YOUNG ADULT;

EID: 72949087812     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2008.50     Document Type: Article

References (67)

1. NSDUH Report. Daily Marijuana Users. Survey Report. Rockville, MD: Substance Abuse and Health Services Administration (SAMHSA); 2004.
2. Fisher BA, Ghuran A, Vadamalai V, Antonios TF. Cardiovascular complications induced by cannabis smoking: a case report and review of the literature. Emerg Med J 2005; 22: 679-680.
3. Jones RT. Cardiovascular system effects of marijuana. J Clin Pharmacol 2002; 42: 58S-63S.
4. Aronow WS, Cassidy J. Effect of marihuana and placebo-marihuana smoking on angina pectoris. N Engl J Med 1974; 291: 65-67.
5. Renault PF, Schuster CR, Heinrich R, Freeman DX. Marihuana: standardized smoke administration and dose effect curves on heart rate in humans. Science 1971; 174: 589-591.
6. Aronow WS, Cassidy J. Effect of smoking marihuana and of a high-nicotine cigarette on angina pectoris. Clin Pharmacol Ther 1975; 17: 549-554.
7. Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001; 178: 116-122.
8. Cadet JL, Bolla K, Herning RI. Neurological assessments of marijuana users. Methods Mol Med 2006; 123: 255-268.
9. Lundqvist T. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav 2005; 81: 319-330.
10. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287: 1123-1131.
11. Wilson W, Mathew R, Turkington T, Hawk T, Coleman RE, Provenzale J. Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J Addict Dis 2000; 19: 1-22.
12. Lawson TM, Rees A. Stroke and transient ischaemic attacks in association with substance abuse in a young man. Postgrad Med J 1996; 72: 692-693.
13. McCarron MO, Thomas AM. Cannabis and alcohol in stroke. Postgrad Med J 1997; 73: 448.
14. Mesec A, Rot U, Grad A. Cerebrovascular disease associated with marijuana abuse: a case report. Cerebrovasc Dis 2001; 11: 284-285.
15. Zachariah SB. Stroke after heavy marijuana smoking. Stroke 1991; 22: 406-409.
16. Gaoni Y, Mechoulam R. The isolation and structure of delta-1- tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 1971; 93: 217-224.
17. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-180.
18. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-784.
19. Carlson SM, Najmi A, Whitin JC, Cohen HJ. Improving feature detection and analysis of surface-enhanced laser desorption/ ionization-time of flight mass spectra. Proteomics 2005; 5: 2778-2788.
20. Lin Z, Jenson SD, Lim MS, Elenitoba-Johnson KS. Application of SELDI-TOF mass spectrometry for the identification of differentially expressed proteins in transformed follicular lymphoma. Mod Pathol 2004; 17: 670-678.
21. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-577.
22. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002; 48: 1835-1843.
23. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 3609-3614.
24. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296-1304.
25. Huang JT, Wang L, Prabakaran S, Wengenroth M, Lockstone HE, Koethe D et al. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry; e-pub ahead of print: published online 16 October 2007.
26. Gold MS, Graham NA, Kobeissy FH, Pepine CJ, Goldberger BA. Speed, cocaine, and other psychostimulants death rates. Am J Cardiol 2007; 100: 1184.
27. McLellan AT, Luborsky L, O'Brien CP, Barr HL, Evans F. Alcohol and drug abuse treatment in three different populations: is there improvement and is it predictable? Am J Drug Alcohol Abuse 1986; 12: 101-120.
28. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology 2002; 59: 1337-1343.
29. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003; 2: 1096-1103.
30. Righetti PG, Castagna A, Antonioli P, Boschetti E. Prefractionation techniques in proteome analysis: the mining tools of the third millennium. Electrophoresis 2005; 26: 297-319.
31. Le Bihan MC, Tarelli E, Coulton GR. Evaluation of an integrated strategy for proteomic profiling of skeletal muscle. Proteomics 2004; 4: 2739-2753.
32. Aryana A, Williams MA. Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? Int J Cardiol 2007; 118: 141-144.
33. Hospattankar AV, Fairwell T, Meng M, Ronan R, Brewer Jr HB. Identification of sequence homology between human plasma apolipoprotein B-100 and apolipoprotein B-48. J Biol Chem 1986; 261: 9102-9104. (Pubitemid 17218177)
34. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999; 19: 472-484.
35. Ito Y, Breslow JL, Chait BT. Apolipoprotein C-III0 lacks carbohydrate residues: use of mass spectrometry to study apolipoprotein structure. J Lipid Res 1989; 30: 1781-1787.
36. Kashyap ML, Srivastava LS, Hynd BA, Gartside PS, Perisutti G. Quantitation of human apolipoprotein C-III and its subspecies by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia. J Lipid Res 1981; 22: 800-810.
37. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipo-protein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986; 78: 1287-1295.
38. Kinnunen PK, Ehnolm C. Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett 1976; 65: 354-357.
39. Weber P, Raederstorff D. Triglyceride-lowering effect of omega-3 LC-polyunsaturated fatty acids-a review. Nutr Metab Cardiovasc Dis 2000; 10: 28-37.
40. Carlson LA, Ballantyne D. Changing relative proportions of apolipoproteins CII and CIII of very low density lipoproteins in hypertriglyceridaemia. Atherosclerosis 1976; 23: 563-568.
41. Malmendier CL, Delcroix C, Lontie JF. Kinetics of a heterogeneous population of particles in low density lipoprotein apolipoprotein B. Atherosclerosis 1989; 80: 91-100.
42. Schonfeld G, George PK, Miller J, Reilly P, Witztum J. Apolipo-protein C-II and C-III levels in hyperlipoproteinemia. Metabolism 1979; 28: 1001-1010.
43. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertrigly-ceridemia as a result of human Apo CIII gene expression in transgenic mice. Science 1990; 249: 790-793.
44. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertri-glyceridemia. J Biol Chem 1994; 269: 23610-23616.
45. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006; 114: 681-687.
46. Kalofoutis A, Dionyssiou-Asteriou A, Maravelias C, Koutselinis A. Changes of HDL-lipid composition as related to delta 9-THC action. Pharmacol Biochem Behav 1985; 22: 343-345.
47. Panin LE, Shalbueva NI, Polyakov LM. Effects of apolipoproteins C on oxidative phosphorylation in rat liver mitochondria. Bull Exp Biol Med 2000; 130: 769-771.
48. Sarafian TA, Habib N, Oldham M, Seeram N, Lee RP, Lin L et al. Inhaled marijuana smoke disrupts mitochondrial energetics in pulmonary epithelial cells in vivo. Am J Physiol Lung Cell Mol Physiol 2006; 290: L1202-L1209.
49. Ponto LL, O'Leary DS, Koeppel J, Block RI, Watkins GL, Richmond JC et al. Effect of acute marijuana on cardiovascular function and central nervous system pharmacokinetics of [(15)O] water: effect in occasional and chronic users. J Clin Pharmacol 2004; 44: 751-766.
50. Benowitz NL, Jones RT. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol 1981; 21: 214S-223S.
51. Beaconsfield P, Ginsburg J, Rainsbury R. Marihuana smoking. Cardiovascular effects in man and possible mechanisms. N Engl J Med 1972; 287: 209-212.
52. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397. (Pubitemid 40523733)
53. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134.
54. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996; 91: 1585-1614.
55. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305.
56. Cote M, Mauriege P, Bergeron J, Almeras N, Tremblay A, Lemieux I et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 2005; 90: 1434-1439.
57. Nong L, Newton C, Cheng Q, Friedman H, Roth MD, Klein TW. Altered cannabinoid receptor mRNA expression in peripheral blood mononuclear cells from marijuana smokers. J Neuroimmu-nol 2002; 127: 169-176.
58. Zannis VI, Kan HY, Kritis A, Zanni E, Kardassis D. Transcriptional regulation of the human apolipoprotein genes. Front Biosci 2001; 6: D456-D504.
59. Gruber PJ, Torres-Rosado A, Wolak ML, Leff T. Apo CIII gene transcription is regulated by a cytokine inducible NF-kappa B element. Nucleic Acids Res 1994; 22: 2417-2422.
60. Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol 2004; 173: 2373-2382.
61. Feingold KR, Soued M, Serio MK, Moser AH, Dinarello CA, Grunfeld C. Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology 1989; 125: 267-274.
62. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882-888.
63. Lee SJ, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003; 23: 853-858.
64. Herning RI, Better WE, Tate K, Cadet JL. Marijuana abusers are at increased risk for stroke. Preliminary evidence from cerebrovascular perfusion data. Ann N Y Acad Sci 2001; 939: 413-415.
65. Herning RI, Better W, Tate K, Cadet JL. EEG deficits in chronic marijuana abusers during monitored abstinence: preliminary findings. Ann N Y Acad Sci 2003; 993: 75-78; discussion 79-81.
66. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 2003; 9: 94-101.
67. Hirsch-Reinshagen V, Wellington CL. Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease. Curr Opin Lipidol 2007; 18: 325-332.